Comprehensive Transcriptional Analysis of Early-Stage Urothelial CarcinomaJakob Hedegaard, Lars Dyrskjøt, Philippe Lamy et al.|Cancer Cell|2016Cited by 654
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analysesMontserrat García‐Closas, Nathaniel Rothman, Núria Malats et al.|The Lancet|2005Cited by 631
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancerSia V. Lindskrog, Lars Dyrskjøt, Frederik Prip et al.|Nature Communications|2021Cited by 381
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with OutcomeYves Allory, Francisco X. Real, Willemien Beukers et al.|European Urology|2013Cited by 289
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitisHeiko Witt, Thomas Berg, Hans-Ulrich Schulz et al.|Nature Genetics|2006Cited by 250